Home / Healthcare / Medical Device / Home Infusion Therapy Market
Home Infusion Therapy Market Size, Share & Industry Analysis, By Product (Devices, Drugs, and Services), By Indication (Anti-Infective, Chemotherapy, Hydration Therapy, Enteral Nutrition, Total Parenteral Nutrition, Immunoglobulin Therapy, and Others), and Regional Forecast, 2024-2032
Report Format: PDF | Latest Update: Jun, 2024 | Published Date: May, 2024 | Report ID: FBI102989 | Status : PublishedThe global home infusion therapy market size was USD 37.72 billion in 2023. The market is projected to grow from USD 39.84 billion in 2024 to USD 92.23 billion by 2032 at a CAGR of 11.1% over the forecast period. North America dominated the global market with a share of 41.78% in 2023.
According to the 2023 Home Care Chartbook from the Research Institute for Home Care (RIHC), as of 2022, there were 11,353 active home health agencies in the U.S. This number was 11,474 in 2021, 11,565 in 2020, and 11,569 in 2019. Also, as per to the CMS, home health services are encompassed below the Medicare benefit program. Home infusion therapy is defined as a process in which patients receive biologics & drugs at home. This also includes nursing services that provide, train, and educates patients about the safe intravenous administration of drugs.
Receiving care at home rather than a healthcare facility or other care places has become a cost-effective option for patients. It has reduced hospital costs, which plays a vital role in boosting the demand for this therapy across the globe. Various government programs are being implemented to shift patients towards home care and reduce the overall hospitalization and treatment costs. Additionally, the rise in preference for homecare amid patients, particularly for infusion treatment, and the growing developments in infusion healing devices designed for home usage are some key factors anticipated to fuel the market.
Amid the prevailing coronavirus outbreak, various countries delayed or postponed all elective procedures. Although infusion treatment is not elective, the presence of home infusion therapy as an alternative to infusion healing at hospitals has limited the registration of such patients in hospital settings. The primary reason includes hospitals being overburdened by the COVID-19 patients and a majority of resources being diverted to manage the COVID-19 pandemic. Due to this, many patients shifted towards house-based care to continue infusion therapies. This led to an increase in the amount of patients getting infusion therapy at home in 2020.
Many home infusion service providers, such as Option Care Health Inc., are working in collaboration with hospitals to facilitate the shift of patients at home care settings to receive treatment. Additionally, the house infusion service providers are building a strong network with pharmacies to develop a personalized development care strategy and provide customized medications & supplies to patients in need of infusion therapies at home. These factors have exerted a positive impact on demand for home infusion supplies and services, especially in developed countries.
Furthermore, the implementation of regulations by the Centers for Medicare & Medicaid Services (CMC) waived off the need for nurses and physicians to visit patients at home and directed the visits to be held via Telehealth platforms. Virtual patient handling offers certain drawbacks as it becomes difficult for caregivers to obtain import data through a video call. This is projected to slightly hinder the uptake of infusion healing at one’s residence, especially among hospitalized patients. However, initiatives taken by various governments for the progression of new reimbursement stratagems, offering cost-effective infusion products & services to the patients at home are likely to pose a positive impact on the market during coronavirus pandemic.
Home Infusion Therapy Market Trends
Dramatic Shift towards Home Medical Care to Boost Market Growth
As the healthcare sector is witnessing drastic changes over the past years, residential medical care is becoming the popular choice among patients. There is a progressive fluctuation of patients and healthcare providers to treat non-critical conditions in outpatient settings, including home care settings. Various for-profit and private companies have entered the service sector and are training medical personnel for the delivery of infusion therapy benefits to patients at home.
Patient preference toward home infusion settings is anticipated to grow in the near future owing to the high patient convenience and the launch of new, innovative therapies that can be easily and safely cost-effectively administered in home settings. The recent COVID-19 pandemic accelerated this trend more significantly. Furthermore, advancements in technology, such as the use of wearables, advances in point-of-care technology, and increasing adoption of telemedicine, have resulted in better remote monitoring and thereby enable safer care in the home.
Various comparative studies have demonstrated a substantial cost reduction for providing specialty infusion drugs in homes compared to hospital settings. For instance, as per various studies, the cost of IVIG infusion at Accredo in the home infusion setting is 62% lower than medical office administration costs and 87% lower than hospital outpatient administration costs. This has been pivotal in attracting a large patient pool towards adopting treatment at residence as a preferred healing choice. Along with this, efforts were undertaken by many healthcare organizations in promoting homecare, and an increase in the number of players offering a wide range of services is likely to increase the demand for home infusion products & services during the forecast period.
Home Infusion Therapy Market Growth Factors
Rising Prevalence of Chronic Disease and Rise in Geriatric Population to Fuel Demand
The burden of chronic diseases is rapidly increasing globally. There has been a tremendous rise in the incidences of chronic immune deficiencies, cancer, diabetes, and congestive heart failure, and others. According to the World Health Organization (WHO), chronic diseases affect approximately 133 million Americans, representing 40% of the total population of the country. This is predicted to lead to a large patient pool suffering from chronic diseases, along with patients undergoing infusion therapy at house settings.
A rise in the geriatric population is also boosting the market growth. This population is more prone to chronic diseases, which, in turn, results in more demand for treatment at home. For instance, according to a survey conducted by the American Association of Retired People, the majority of older adults prefer to remain in their own homes for as long as possible. Also, according to the Dartmouth Atlas researchers, in the U.S., more than 80% of patients wish to avoid hospitalization and intensive care during the terminal phase of their life and prefer to be treated at home.
The cases of chronic diseases would also continue to increase in the future driven not only by the rising geriatric population but also the high prevalence of these diseases among children and younger adults.
Moreover, growing awareness about the welfares associated with home treatment modality and rapid technological progressions in the devices designed for home use are some of the additional factors probable to fuel the demand for home infusion therapy globally during the forecast period.
Rising Demand for Home Care Intravenous Drug Infusion Therapy to Augment Growth
The rising prevalence of hospital-acquired infections is one of the major factors endorsing the home infusion therapy market growth. Globally, hospital-gained infections are on the rise owing to the elongated inpatient hospital stays and have currently become one of the major safety concerns among healthcare providers.
According to the Center for Disease Control (CDC) an estimated 1.7 million patients in the U.S. are infected with hospital-attained infection every year. The immune-negotiated patients receiving infusion therapy at hospitals are at greater risk, making home care setting the best alternative to receiving safe treatment, further augmenting the preference towards home infusion therapy among patients.
RESTRAINING FACTORS
Limited Reimbursement for Homecare to Restrict Market Growth
One of the major factors probable to hinder market growth is the absence of reimbursement policies in many developing nations. Depending on the therapy provided and the indication, the reimbursement rates are variable for home infusion therapy. The out-of-pocket expenditure on healthcare in emerging nations such as India and China is higher compared to other nations with an established reimbursement structure. The circumstance is further compounded by the lack of reimbursement policies for home care settings in these countries.
This has constrained the number of patients undergoing home infusion therapy in emerging countries. This, along with a limited number of public and private house infusion providers in emerging countries, lack of trained medical personnel, and other limited resources, is expected to limit the adoption of these services.
Home Infusion Therapy Market Segmentation Analysis
By Product Analysis
Robust Drug Pipeline to Support Drugs Segment Dominate Market
Based on product type, the market is segmented into devices, drugs, and services. The drug segment held the largest market share in 2023. The growing incidence of cancer and other chronic and acute conditions globally, and the strong infused drug pipeline is likely to boost the growth of the drug segment during the forecast period. In addition, the supportive regulatory bodies leading to an increasing number of product approvals also support the market growth. For instance, the U.S. FDA has approved more than 100 infusible drugs from 2016 to 2022.
The service segment is anticipated to witness significant growth during the forecast period, owing to the rise in the healthcare professionals and the services offered by global and domestic players.
The devices segment is likely to witness the second-highest growth after the services segment during the forecast period owing to the increasing number of new entrants in the market and growing innovations in the medication delivery systems for various indications.
By Indication Analysis
Rising Awareness Regarding Benefits of Receiving Chemotherapy at Home to boost Chemotherapy Segment Growth during Forecast Period
In terms of indication, the market is segmented into enteral nutrition, anti-infective, chemotherapy, parenteral nutrition, hydration therapy, intravenous immunoglobulin, and others.
The anti-infective segment dominated the market in 2023 owing to the higher prevalence of infectious diseases, ease of set-up, and low cost of the therapy. Moreover, the usage of anti-infective therapies after every other infusion therapy to reduce the chances of infection in patients due to the use of catheters, which is further propelling the popularity of this segment.
The chemotherapy segment is estimated to witness the highest growth during the forecast period. The massive increase in the prevalence of cancer worldwide and the rise in awareness about the benefits of chemotherapy conducted at one’s own residence are likely to accelerate the growth of the chemotherapy segment in the future. According to the American Cancer Society, an estimated 1.8 million new cancer cases were registered in the U.S. alone in 2020.
The IVIG therapy segment is estimated to witness strong growth during the forecast period owing to the rise in prevalence of primary immunodeficiency diseases such as hypogammaglobinemia and congenital AIDS coupled with new SCIG product approvals of IG.
REGIONAL INSIGHTS
The home infusion therapy market size in North America was worth USD 15.76 billion in 2023, owing to the rapid adoption of therapy and the presence of key players in this region. Moreover, a growing number of patients opting for infusion therapy at home is likely to foster the market in the region. As per a report published by Becker’s Healthcare in 2019, around 3 million patients in the U.S. received house infusions for various indications, a 300% increase since the last decade.
On the other hand, the market in Europe is projected to grow with a significant growth rate owing to the rising geriatric population coupled with the growing chronic disease burden and increasing number of initiatives by the government and market players towards home infusion therapy in the region. For instance, in January 2021, Eitan Medical, a global leader in advanced infusion therapy and drug delivery solutions, launched a U.K. operation to improve its support of the Sapphire infusion pump customers, which includes NHS trusts, private hospitals, and house-care providers.
The market in Asia Pacific is projected to witness significant growth by registering the highest CAGR during the forecast period. This is accredited to the growing awareness about this treatment used to treat a wide range of chronic disorders and the rise in the adoption of innovative technologies. Moreover, the increasing prevalence of cancer, diabetes and other long-term chronic diseases and rise in the patient pool are likely to boost the market in Asia Pacific during the forecast period.
The market in rest of the world is in a nascent stage; however, owing to the higher awareness among the population and gradual shift of preference towards the home medical care is expected to augment the market growth in the region during the forecast period.
List of Key Companies in Home Infusion Therapy Market
Strong Product Portfolio of Market Leaders to Help Strengthen their Position in Market
The competitive scenario of the market is consolidated with the existence of a minority of players such as Braun Melsungen AG, Optum, Inc., Option Care Health Inc., Baxter, and B. These companies are majorly focused on developing innovative infusion pumps and emphasize expanding their geographical footprints in both domestic & international markets. Additionally, in the financial year 2020, the key players reported a significant growth in their revenues from the home infusion treatment services owing to the significant increase in the number of patients receiving infusion healing at house during the COVID-19 restrictions.
- For instance, Option Care Health, Inc. witnessed a 30.1% increase in its revenue in 2020 compared to the prior year and was valued at USD 3,302.6 million.
Moreover, the key players also focused on introducing various new services for in-home infusion coupled with various strategic collaborations to provide easy access to the patients during the COVID-19. For instance, in January 2021, CVS Health collaborated with the Cancer Treatment Centers of America (CTCA) to increase access to chemotherapy at house for eligible patients.
On the other hand, small market manufacturers are emphasizing on expanding their base in developing nations, thereby developing a relatively large number of delivery devices and supplies meant for homecare health facilities.
LIST OF KEY COMPANIES PROFILED:
- Option Care Health Inc. (Illinois, U.S.)
- Optum, Inc. (Eden Prairie, U.S.)
- CareCentrix, Inc. (Hartford, U.S.)
- CVS Health (Woonsocket, Rhode Island, U.S.)
- KabaFusion (Cerritos, U.S.)
- PromptCare (New Jersey, U.S.)
- Baxter International Inc. (Deerfield, U.S.)
- Infusystem (Michigan, U.S.)
KEY INDUSTRY DEVELOPMENTS:
- January 2024 - BrightStar Care collaborated with Paragon Healthcare to offer high-quality home infusion services in the U.S.
- August 2023 - NeuroNet Pro and WeInfuse collaborated to offer advanced workflow solutions for infusion therapy in neurology practices.
- June 2023 - Yale New Haven Health and CarepathRx announced their partnership for home infusion services.
- March 2021 – PromptCare acquired NBN Infusions, Inc., a New Jersey-based home infusion and respiratory therapy service provider. NBN Infusions, Inc. majorly provides infusion therapy services for critically conditioned patients. In this acquisition, PromptCare acquired all assets of NBN Infusions, Inc. This acquisition will help PromptCare to reinforce its market share in the Northeastern U.S.
- February 2020 – Avoset developed a homecare system, AvosetGO, an infusion pump device with embedded touch screens which can be connected and watched over via smart devices.
REPORT COVERAGE
The global home infusion therapy market report provides a detailed analysis of the market and focuses on key aspects such as the global prevalence of chronic diseases, technological advancements in infusion drug delivery devices, and others. Besides this, the report offers insights into the market, current trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the market over recent years.
Report Scope & Segmentation
ATTRIBUTE | DETAILS |
Study Period | 2019-2032 |
Base Year | 2023 |
Estimated Year | 2024 |
Forecast Period | 2024-2032 |
Historical Period | 2019-2022 |
Growth Rate | CAGR of 11.1% from 2024-2032 |
Unit | Value (USD billion) |
Segmentation | By Product
|
By Indication
| |
By Geography
|
Frequently Asked Questions
How much is the home infusion therapy market worth?
Fortune Business Insights says that the global market size was USD 37.72 billion in 2023 and is projected to reach USD 92.23 billion by 2032.
What was the value of the North America home infusion therapy market in 2023?
In 2023, the North America market value stood at USD 15.76 billion.
At what CAGR is the market projected to grow over the forecast period (2024-2032)?
Growing at a CAGR of 11.1%, the market will exhibit steady growth over the forecast period (2024-2032).
What is the leading segment in the market by type of product?
Drug segment is expected to be the leading product segment in this market during the forecast period.
What is the key factor driving the market?
Growing demand for effective drug delivery devices, changes in the shift towards home medical care, rise in prevalence of chronic diseases, and the growing number of players are the key drivers of the market.
Who are the top players in the market?
Optum, Inc., Option Care Health Inc., Baxter, and B. Braun Melsungen AG are among the top in the global market.
Which region held the highest market share in 2023?
North America dominated the market share in 2023.
- Global
- 2023
- 2019-2022
- 128